tbuckley/cabot-search huggingface dataset:
Arsenic trioxide‐ and idarubicin‐induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study
Authors: Y.L. Kwong, W.Y. Au, C.S. Chim, A. Pang, C. Suen, R. Liang
Journal: American Journal of Hematology (2001)

Abstract Arsenic trioxide (As 2 O 3 ) effectively induces remissions in relapsed acute promyelocytic leukaemia (APL), but the safety of its long‐term administration is unknown. The anthracycline idarubicin is highly active alone or in combination chemotherapy for the treatment of APL. To minimize arsenic exposure and based on the high sensitivity of APL cells to anthracyclines, we conducted a prospective study to evaluate induction with As 2 O 3 followed by consolidation with idarubicin in the treatment of APL in relapse. Eight patients were treated with As 2 O 3 at a daily dose of 10 mg until remission, followed by three monthly courses of idarubicin, at 6 mg/m 2 /day for 5 days in the first course and 6 mg/m 2 /day for 2 days in the subsequent two courses. All patients achieved morphological but not molecular remission after As 2 O 3 treatment. During As 2 O 3 therapy, an increase in white cell count peaking at a median of 17 days occurred in all the cases. Serial flow cytometric analysis of apoptosis, with mitochondrial APO2.7 antigen expression and the sub‐G1 cell fraction on DNA histogram as markers, showed induction of apoptosis of APL cells in vivo. With both qualitative and real‐time quantitative polymerase chain reaction, all patients were shown to attain molecular remission after subsequent idarubicin treatment. With a median follow up of 13 months, seven of eight patients have remained in complete clinical remission, with six patients in molecular remission as well. One patient who was in third remission became PCR‐positive after being transiently negative. One patient died from an intracranial extramedullary relapse after achieving marrow molecular remission. We conclude that As 2 O 3 induction followed by idarubicin consolidation is an effective therapy for APL in relapse. This regimen avoids the possible long‐term toxicities of As 2 O 3 and mutagenicity of combination chemotherapy, a strategy that might be suitable for this potentially curable leukaemia. Am. J. Hematol. 66:274–279, 2001. © 2001 Wiley‐Liss, Inc.
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Authors: Fred Poordad, Christophe Hezode, Roger Trinh, Kris V. Kowdley, Stefan Zeuzem, Kosh Agarwal, Mitchell L. Shiffman, Heiner Wedemeyer, Thomas Berg, Eric M. Yoshida, Xavier Forns, Sandra S. Lovell, Barbara Da Silva-Tillmann, Christine A. Collins, Andrew L. Campbell, Thomas Podsadecki, Barry Bernstein
Journal: New England Journal of Medicine (2014)

Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis.We randomly assigned 380 patients with Child-Pugh class A cirrhosis to receive either 12 or 24 weeks of treatment with ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir (250 mg twice daily), and ribavirin administered according to body weight. The primary efficacy end point was a sustained virologic response 12 weeks after the end of treatment. The rate of sustained virologic response in each group was compared with the estimated rate with a telaprevir-based regimen (47%; 95% confidence interval [CI], 41 to 54). A noninferiority margin of 10.5 percentage points established 43% as the noninferiority threshold; the superiority threshold was 54%.A total of 191 of 208 patients who received 12 weeks of treatment had a sustained virologic response at post-treatment week 12, for a rate of 91.8% (97.5% CI, 87.6 to 96.1). A total of 165 of 172 patients who received 24 weeks of treatment had a sustained virologic response at post-treatment week 12, for a rate of 95.9% (97.5% CI, 92.6 to 99.3). These rates were superior to the historical control rate. The three most common adverse events were fatigue (in 32.7% of patients in the 12-week group and 46.5% of patients in the 24-week group), headache (in 27.9% and 30.8%, respectively), and nausea (in 17.8% and 20.3%, respectively). The hemoglobin level was less than 10 g per deciliter in 7.2% and 11.0% of patients in the respective groups. Overall, 2.1% of patients discontinued treatment owing to adverse events.In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virologic response. Drug discontinuations due to adverse events were infrequent. (Funded by AbbVie; TURQUOISE-II ClinicalTrials.gov number, NCT01704755.).
Pediatric Acute Pyelonephritis
Authors: Jan Stauss, Leonard P. Connolly, Jeannette Perez–Rossello, S Ted Treves
Journal: Clinical Nuclear Medicine (2003)

Symptoms are commonly nonspecific in children with acute pyelonephritis; therefore, other diagnoses may be considered first. Skeletal scintigraphy revealed abnormal tracer distribution in the left kidney of a 7-year-old girl suspected of having acute osteomyelitis. A diagnosis of acute pyelonephritis was suggested and later supported by computed tomography and urine culture.
Acute generalized exanthematous pustulosis following use of ticlopidine
Authors: S.P. Cannavò, F. Borgia, F. Guarneri, M. Vaccaro
Journal: British Journal of Dermatology (2000)

S ir, Ticlopidine is a platelet aggregation inhibitor widely used for secondary prevention of cerebrovascular accidents in patients predisposed to thrombosis. In addition to haematological side‐effects such as purpura and ecchymosis, bone marrow aplasia, and jaundice and cholestatic hepatitis, this drug may induce numerous cutaneous adverse drug reactions: pruritus, urticaria, exanthemata, hyperhidrosis, lupus erythematosus and vasculitis; 1 to the best of our knowledge, acute generalized exanthematous pustulosis (AGEP) following use of ticlopidine has not previously been reported. A 66‐year‐old woman, with a previous history of ischaemic heart disease, started oral ticlopidine (Tiklid, Sanofi Winthrop Industrie, Ambares, France) 250 mg daily, to prevent thrombosis, in March 1998. She was on no other medication, and there was no personal or family history of psoriasis. After 3 weeks, she was referred to our department with an acute, febrile (39 °C), pruritic rash. This began on the trunk and subsequently spread to the extremities; the face, palms and soles were spared and there was no mucosal involvement. Examination showed several hundred superficial, small (1–3 mm diameter), non‐follicular pustules on an erythematous base ( Fig. 1), with maceration at the axillae and groins. Laboratory findings revealed leucocytosis (white cell count 29·4 × 109/L) with a polymorphonuclear count of 21·1 × 109/L; the erythrocyte sedimentation rate was 43 mm in the first hour. Blood culture was sterile, and negative results were obtained in fungal and bacterial cultures from the pustules, and serological tests for cytomegalovirus, Epstein–Barr virus, parvovirus B19 and Coxsackie virus. Skin biopsy demonstrated subcorneal pustules with neutrophils and a perivascular inflammatory cell infiltrate in the papillary dermis.
F-18 FDG PET/CT in Pulmonary Alveolar Proteinosis
Authors: Chun-Wei Hsu, Feng-Yuan Liu, Chih-Wei Wang, Horng-Chyuan Lin, Chien-Da Huang
Journal: Clinical Nuclear Medicine (2009)

Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by an accumulation of periodic acid-Schiff positive lipoproteinaceous material in the alveolar space. A 67-year-old smoking man was diagnosed with PAP in December 2003. We present the case of PAP with mild and heterogeneous accumulation of F-18 fluorodeoxyglucose (FDG) in both lungs shown on the combined F-18 FDG positron emission tomography and computed tomography. Increased rates of glucose utilization by the inflammatory cells involved in the pathogenesis of PAP might explain the mildly increased pulmonary F-18 FDG uptake we observed.
Omission of Elective Nodal Irradiation Has No Impact on Isolated Elective Nodal Failure and Survival Outcomes in Stage Iii Non-Small-Cell Lung Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy
Authors: E. Topkan, O.C. Guler, B.A. Yildirim
Journal: Annals of Oncology (2015)
Surgical Treatment of Double-Outlet Left Ventricle
Authors: ALBERT D. PACIFICO, JOHN W. KIRKLIN, L. M. BARGERON, BENIGNO SOTO
Journal: Circulation (1973)

Four patients with double-outlet left ventricle and ventricular septal defect have been successfully corrected surgically. Three of the patients had pulmonary stenosis, and one did not. Three patients had d -position of the great arteries, and one patient had l -position with the aorta anterior and to the left. Surgical correction was accomplished by repairing the ventricular septal defect, closing the connection between left ventricle and pulmonary artery, and creating a conduit between right ventricle and pulmonary artery. The preferred conduit is a composite valved one.
American College of Cardiology and American Heart Association Methodology for the Selection and Creation of Performance Measures for Quantifying the Quality of Cardiovascular Care
Authors: John A. Spertus, Kim A. Eagle, Harlan M. Krumholz, Kristi R. Mitchell, Sharon-Lise T. Normand
Journal: Circulation (2005)

The ability to quantify the quality of cardiovascular care critically depends on the translation of recommendations for high-quality care into the measurement of that care. As payers and regulatory agencies increasingly seek to quantify healthcare quality, the implications of the measurement process on practicing physicians are likely to grow. This statement describes the methodology by which the American College of Cardiology and the American Heart Association approach creating performance measures and devising techniques for quantifying those aspects of care that directly reflect the quality of cardiovascular care. Methods for defining target populations, identifying dimensions of care, synthesizing the literature, and operationalizing the process of selecting measures are proposed. It is hoped that new sets of measures will be created through the implementation of this approach, and consequently, through the use of such measurement sets in the context of quality improvement efforts, the quality of cardiovascular care will improve.
Tackling female genital mutilation in the UK
Authors: Sarah M Creighton, Zimran Samuel, Naana Otoo-Oyortey, Deborah Hodes
Journal: BMJ (2019)

Intercollegiate recommendations are welcome, but where is the action plan?

As a result of the diaspora of communities that practise female genital mutilation, many more women are now living with genital mutilation in the United Kingdom, and many more girls are at risk. The campaign to end the practice in the UK has been spearheaded by committed and experienced activists (www.forwarduk.org.uk, www.equalitynow.org with wide institutional endorsement),1 as reflected in recent intercollegiate recommendations for dealing with the problem.2

The document results from collaboration between the Royal College of Obstetricians and Gynaecologists, the Royal College of Midwives, the Royal College of Nursing, Equality Now, and the Unite union. It merges key points from several existing guidelines3 4 5 6 into a single paper that reiterates the core message: female genital mutilation is a form of child abuse. It points to the importance of data collection and sharing between relevant agencies for effective action. It stipulates appropriate professional care for girls and young women affected by the practice. For the recommendations to be implemented (we hope urgently), a strategic implementation plan with a tight time frame is …
Detection and Surveillance of Colorectal Cancer
Authors: Mark W. Ragozzino
Journal: JAMA (1990)

Colorectal cancer is the second most common cause of cancer in the United States. The overall mortality rate approaches 60%. However, the detection of early lesions results in a mortality rate of 20% or less. Therefore, if improvement in survival is to occur, increased efforts need to be focused not only on primary prevention but also on early detection of malignant lesions and the eradication of potentially malignant lesions. There is no universal consensus as to how this can be accomplished. The purpose of this article is to serve as a guideline, providing a practical basis for improving early detection and management of colorectal cancer and its precursors.
Preclinical target validation using patient-derived cells
Authors: Aled M. Edwards, Cheryl H. Arrowsmith, Chas Bountra, Mark E. Bunnage, Marc Feldmann, Julian C. Knight, Dhavalkumar D. Patel, Panagiotis Prinos, Michael D. Taylor, Michael Sundström, Phil Barker, Dalia Barsyte, Mario H. Bengtson, Cindy Bell, Paul Bowness, Kym M. Boycott, Carolyn Buser-Doepner, Christopher L. Carpenter, Andrew J. Carr, Kirk Clark, Anuk M. Das, Dashyant Dhanak, Peter Dirks, James Ellis, Valeria R. Fantin, Christopher Flores, Edward A. Fon, Donald E. Frail, Opher Gileadi, Ronan C. O'Hagan, Trevor Howe, John T. R. Isaac, Nada Jabado, Per-Johan Jakobsson, Lars Klareskog, Stefan Knapp, Wen Hwa Lee, Evelyne Lima-Fernandes, Ingrid E. Lundberg, John Marshall, Katlin B. Massirer, Alex E. MacKenzie, Tetsuyuki Maruyama, Anke Mueller-Fahrnow, Senthil Muthuswamy, Jagdeep Nanchahal, Catherine O'Brien, Udo Oppermann, Nils Ostermann, Kevin Petrecca, Bruce G. Pollock, Viviane Poupon, Rab K. Prinjha, Saul H. Rosenberg, Guy Rouleau, Malcolm Skingle, Arthur S. Slutsky, Garth A. M. Smith, Dominique Verhelle, Hans Widmer, L. Trevor Young
Journal: Nature Reviews Drug Discovery (2015)
Asternia with aplasia cutis: a method of repair.
Authors: E Cardoso, M S Sundararajan
Journal: Thorax (1987)

Asternia is the rarest of developmental anomalies which affect the sternum.The first case of asternia documented in an English publication was in 1968.1 Subsequently seven more have been described.We report absence of the sternum in a child with an associated skin defect, successfully repaired by pectoral fasciorrhaphy and a rectus abdominis myocutaneous flap.Case report
Natural number concepts: No derivation without formalization
Authors: Paul Pietroski, Jeffrey Lidz
Journal: Behavioral and Brain Sciences (2008)

Abstract The conceptual building blocks suggested by developmental psychologists may yet play a role in how the human learner arrives at an understanding of natural number. The proposal of Rips et al. faces a challenge, yet to be met, faced by all developmental proposals: to describe the logical space in which learners ever acquire new concepts.
Abstract 592: Downregulation of uPAR and uPA retards angiogenesis and proliferation and activates the extrinsic apoptotic pathway in pancreatic cancer cells
Authors: Bharathi Gorantla, Jasti S. Rao, Jitendra Patel, Christopher S. Gondi
Journal: Cancer Research (2010)

Abstract Pancreatic cancer is one of the major causes of mortality in the United States. Despite well established chemotherapy and surgical resection strategies, the five-year mean survival rate is less than five percent. The activation of the uPAR/uPA system is an early event in the development of pancreatic ductal adenocarcinoma (PDAC), and uPAR gene amplification identifies a subgroup of particularly aggressive tumors. In the present study, we used two pancreatic cancer cell lines [MIA PaCa-2 (CRL1420) and PANC-1 (CRL1469)] to demonstrate the effect of uPA and uPAR downregulation. From the results, we observed that RNAi-expressing plasmids efficiently downregulated the expression of uPAR and uPA both at the mRNA and protein levels. In vitro and in vivo angiogenic assays revealed a significant decrease in angiogenic potential of CRL1420 (in vitro 26±3% and in vivo 13±2%) and CRL1469 (in vitro 23±1% and in vivo 10±2%) cells that were downregulated for both uPA and uPAR. From the antibody array analysis, we observed that the simultaneous downregulation of uPAR and uPA subsequently caused the downregulation of angiogenin and the overexpression of RANTES. The MTT proliferation assay results demonstrated that the downregulation of uPAR alone caused a decrease in proliferation (CRL1420: 24±3%; CRL1469: 38±2%) and downregulation of uPA alone caused a lesser decrease in proliferation (CRL1420: 19±2%; CRL1469: 26±1%) whereas the simultaneous downregulation of both uPA and uPAR caused the most significant decrease in proliferation in both cell lines (CRL1420: 84±4%; CRL1469: 93±3%). Further, FACS analysis demonstrated that the simultaneous downregulation of uPAR and uPA caused the accumulation of cells in the sub-G0/1 phase in both CRL1420 and CRL1469 cells. In addition, western blot analysis revealed that downregulation of uPA and uPAR caused the activation of caspase 8 and induced the cleavage of PARP, which is indicative of apoptosis; these results were confirmed by TUNEL assay. In conclusion, our results clearly demonstrate that the targeting of the uPAR-uPA system has potential clinical relevance for the treatment of pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 592.
674 HEPATOCYTE-SPECIFIC DELETION OF CFLIP ENHANCES LIVER INJURY FROM STREPTOZOTOCIN-INDUCED HYPERGLYCEMIA INVOLVING ACTIVATION OF JNK
Authors: J.M. Schattenberg, T. Kohl, M. Nagel, I. Wagner, A. Kreft, Y.-W. He, P.R. Galle, M. Schuchmann
Journal: Journal of Hepatology (2011)
The Meaning of "Significant Bacteriuria"
Authors: Edward H. Kass
Journal: JAMA (1963)

<h3>To the Editor:</h3> —It is always useful to exchange views in the relative informality of brief communications, and the opportunity to add to Dr. Hinman's remarks is appreciated. Dr. Hinman's remarks are addressed to three points. The first is a precise and accurate statement of the meaning of the term "bacteriuria." The second is an attack on the apparent misuse of the concept of bacteriuria in a few of the studies that have appeared recently in the literature. The third is a general criticism of the use of quantitative criteria of bacteriological diagnosis of infection of the urinary tract in individual patients, as opposed to studies of large populations, because of the statistical nature of the validation of the use of the quantitative approach. Dr. Hinman's analysis, with respect to the first two points, is one with which I have no important disagreements, even in the area in which I
Low-dose Mometasone Furoate/Formoterol: Efficacy and Safety Findings from a Study Investigating a New Combination Therapy in Subjects Whose Asthma was Inadequately Controlled Using Low-Dose Inhaled Corticosteroid
Authors: E. Meltzer, H. Nolte, C. LaForce
Journal: Journal of Allergy and Clinical Immunology (2010)
Familial intrahepatic cholestasis 1: Studies of localization and function
Authors: Peter Ujhazy, Daniel Ortiz, Suniti Misra, Shohua Li, James Moseley, Hugh Jones, Irwin M. Arias
Journal: Hepatology (2001)

Mutations in the FIC1 gene constitute the molecular defect in familial intrahepatic cholestasis I (Fic1 [Byler's disease]) and benign recurrent intrahepatic cholestasis. This report describes the localization of Fic1 in rat liver and intestine, as well as biochemical and transfection studies that support its function as an energy-dependent aminophospholipid translocase. Immunocytochemistry of rat liver and immunoblotting of membrane fractions localized Fic1 to the canalicular, but not basolateral, plasma membrane domain. In the small intestine, Fic1 was localized to the apical membrane of epithelial cells. The distribution of Fic1 in liver plasma membrane fractions from control and taurocholate-treated rats correlated positively with adenosine triphosphate (ATP)-dependent aminophospholipid (phosphatidyl-serine) translocase activity. In canalicular membrane vesicles, translocase activity had an initial velocity of 3.3 nmol phosphatidylserine (PS) translocated per milligram of protein per minute and a K(m) (ATP) = 1.2 mmol/L; was inhibited by vanadate, N-ethylmaleimide, sodium azide, and calcium; and was unidirectional (i.e., from the outer to the inner canalicular plasma membrane leaflet). Transient transfection of CHOK1 cells with FIC1 cDNA resulted in appearance of FIC1 in membrane preparations and energy-dependent PS translocation in cells. These studies indicate that FIC1 is a canalicular P-type ATPase that participates in maintaining the distribution of aminophospholipids between the inner and outer leaflets of the plasma membrane. How this process produces cholestasis is under study.
Polymorphism of Complement C4 and Susceptibility to IDDM and Microvascular Complications
Authors: Karl Lhotta, Martin Auinger, Florian Kronenberg, Karl Irsigler, Paul König
Journal: Diabetes Care (1996)

OBJECTIVE The aim of this study was to investigate whether or not the inherited polymorphism of complement C4 is associated with genetic susceptibility to microvascular complications in IDDM as previously reported. RESEARCH DESIGN AND METHODS We determined C4 phenotypes in 241 patients with IDDM and 140 healthy control subjects by agarose gel electrophoresis and immunoprecipitation. C4 allotype frequencies were compared between patients and healthy control subjects. In addition, we compared allotype frequencies of 83 patients with nephropathy with those of 80 patients without nephropathy and compared those of 50 patients with proliferative retinopathy with those of 68 patients without retinopathy or background retinopathy. Duration of IDDM in control patients was at least 21 years. RESULTS Patients and healthy control subjects differed at both the C4A (P &amp;lt; 0.00001) and C4B (P &amp;lt; 0.0005) loci. The C4 null allele C4AQ0 was significantly increased in IDDM patients (26.8 vs. 11.8%, P &amp;lt; 0.005). C4B2 was more frequently observed in patients (14.5 vs. 6.8%, P &amp;lt; 0.05) compared with healthy control subjects. No differences were observed in C4 allotype distribution between patients with and without nephropathy or retinopathy. CONCLUSIONS These data confirm previous reports of an association between the C4 null allele C4AQ0 and IDDM. Our results do not support an association of the inherited polymorphism of complement C4 with genetic susceptibility to microvascular complications in patients with IDDM.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
Authors: Partow Kebriaei, Michelle A. Detry, Sergio Giralt, Antonio Carrasco-Yalan, Athanasios Anagnostopoulos, Daniel Couriel, Issa F. Khouri, Paolo Anderlini, Chitra Hosing, Amin Alousi, Richard E. Champlin, Marcos de Lima
Journal: Blood (2007)